BBIO vs RARE · rev $438.2M vs rev $350.0M
BridgeBio Pharma Inc (BBIO) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported BBIO revenue for 2026-06-30 was $438.2M. Net income was -$322.4M. BBIO currently screens at market cap $13.24B.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
BBIO currently screens at market cap $13.24B. RARE currently screens at market cap $2.79B.
Not investment advice. Open the BBIO and RARE stock pages for the full models.
Not investment advice.